Cargando…

COVID-19 IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN USE OF IBRUTINIB: NOT THAT RISKY?

Detalles Bibliográficos
Autores principales:	Dourado, M.L.B.F., Eira, V.B.A.S., Matias, G., Baiocchi, O.C.C.G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Editora Ltda. 2020
Materias:	886
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603960/ http://dx.doi.org/10.1016/j.htct.2020.10.888

Ejemplares similares

Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
por: Sittig, Katherine R., et al.
Publicado: (2021)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib
por: Koba, Yusuke, et al.
Publicado: (2023)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
por: Hampel, Paul J., et al.
Publicado: (2022)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
por: Lutz, Mathias, et al.
Publicado: (2017)

Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
por: Molica, Stefano, et al.
Publicado: (2016)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
por: Arthurs, Benjamin, et al.
Publicado: (2017)

Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
por: Liu, Yanyan, et al.
Publicado: (2022)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Clinical course of COVID-19 in a patient with refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) under ibrutinib therapy: a case report
por: Cecyn, Karin Zattar, et al.
Publicado: (2021)

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
por: Montillo, M, et al.
Publicado: (2017)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
por: Okamoto, Koh, et al.
Publicado: (2016)

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
por: Landau, Dan A., et al.
Publicado: (2017)

Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy
por: Voshtina, Ensi, et al.
Publicado: (2018)

Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia
por: Beresford, Rohan, et al.
Publicado: (2019)

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2016)

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
por: Zhou, Hong, et al.
Publicado: (2020)

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
por: Gill, Saar, et al.
Publicado: (2022)

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
por: de Jong, Jan, et al.
Publicado: (2015)

Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia
por: Chavez, Julio C, et al.
Publicado: (2013)

Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment
por: Roy Chowdhury, Subir, et al.
Publicado: (2020)

Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia
por: Garner, Lauren M., et al.
Publicado: (2021)

Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection
por: Fiorcari, Stefania, et al.
Publicado: (2021)

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients
por: Boissard, F, et al.
Publicado: (2015)

Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: McNally, Gretchen Anne, et al.
Publicado: (2015)

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
por: Al‐Katib, Ayad M., et al.
Publicado: (2020)

Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review
por: Sardar, Muhammad, et al.
Publicado: (2019)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report
por: Turcotte, Anna-Eve, et al.
Publicado: (2023)

Fatal Cryptococcal Meningitis in a Patient With Chronic Lymphocytic Leukemia Treated With Ibrutinib
por: Oumayma, Hari, et al.
Publicado: (2023)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
por: Pooler, Darcy B., et al.
Publicado: (2022)

Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
por: Holmes, Katie B., et al.
Publicado: (2019)

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia
por: Tucker, David L, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_c1vsan4j2lp9asbm4mnsurie6o